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Introduction
The development of atherosclerosis is a multifactorial 
process, where the clinical pattern is determined by en-
vironmental and genetic factors. Except for the classical 
risk factors of the atherosclerosis (hypertension [1], lip-
id-metabolic disorders [2], diabetes [3–5] and smoking 
[6]) the clinical signs can be influenced by the genetic 
variants (polymorphisms) [7] of the enzymes responsible 
for the endothelial cell function [8] and for the throm-
botic factors. Inflammatory reaction [9–12] follows the 
primary endothelial injury [13–15] than a generalized 
process starts resulting in atherosclerotic plaque [16] de-
velopment in the small and large arteries of the organ, 
leading to the occlusion of the artery. Diverse clinical 
presentations include myocardial infarction [17], periph-
eral arterial occlusion, dysbasia and gangrene. Besides 
the treatment of symptomes [18–20], it is important to 
explore the metabolic, inflammatory and genetic causes 
of the disease.
The purpose of the study was to examine three ge-
netic polymorphisms of functional genes coding en-
zymes playing a role in the metabolic processes and to 
clarify their role in the vascular pathologys.
The nitric oxide (NO) produced by the endothelial 
nitric oxide synthase (eNOS) has an atheroprotective ef-
fect [21]. Previous studies have shown that the eNOS 
298 Glu/Asp polymorphism causes low NO production, 
which results in hypertension, thrombus development 
and changes in the vascular tone due to the endothelial 
dysfunction, finally leading to atherosclerosis [22–25]. 
The aim of our investigation was to define eNOS Glu-
298Asp (GT) polymorphism in healthy, atherosclerotic 
non-diabetic and diabetic patients. We searched for a 
connection between acute myocardial infarction, stroke 
and the polymorphisms of the eNOS 298 Asp/Asp and 
eNOS 298 Glu/Asp.
It has been known for a long time that high homo-
cystein level of the plasma can destroy the endothel cells 
of the small arteries, which can often be the first step 
towards atherosclerosis, [26–28]. The methylene-tetra-
hydrofolate reductase (MTHFR) C677T enzyme plays 
an important role in the high plasma homocystein levels 
and in the folate metabolism. The TT genotype is usu-
ally associated with higher homocystein levels, so it is 
supposed to increase the risk of atherosclerosis. In our 
examination, we looked for a link between stroke, myo-
cardial infarction and the occurrence of TT/MTHRF 
polymorphism.
The TNF-α plays an important role in the pathophys-
iology of vascular diseases [29] by affecting inflamma-
tory cascade [30, 31], lipid metabolism, obesity and in-
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Abstract: The development of atherosclerosis is a multifactorial process. The purpose of the study was to examine three genetic polymorphisms 
playing a role in the metabolic processes underlying the disease. We compared the data of 348 atherosclerotic non-diabetic patients with 260 
atherosclerotic diabetic patients and 384 healthy controls. We analyzed the prevalence of myocardial infarction and stroke in three different groups 
of patients carrying different polymorphisms. It was proved that if the mutant TT eNOS Glu298ASP variant is present, a significantly higher 
number of myocardial infarctions can be observed than in patients carrying heterozygote GT or normal GG genotype. We proved that in the case 
of MTHFR 677CT heterozygote variants, the occurrence of myocardial infarction is significantly higher and the difference is also significant in 
case of the 677TT homozygote variant. It was verified that among patients with the mutant TNF-α AA genotype the occurrence of cardiovascular 
events was significantly higher. Screening the genetically high risk groups on the long run should be considered as an early detection opportunity 
that may give better chances for prevention and treatment. Understanding the inflammatory mechanisms of the atherosclerosis may give new 
therapeutical targets to pharmacologists.
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sulin resistance. As the degree of the TNF-α expression 
is highly influenced by genetic factors, it is important 
to know how likely atherosclerosis develops in different 
diseases. The promoter region of this gene contains sev-
eral polymorphisms, which influence the TNF-α level. 
In our examination, we have set the aim on the TNF-α 
308GA polymorphisms in atherosclerotic, diabetic and 
healthy patients and we have tried to identify their as-
sociation with myocardial infarction and stroke 
Materials and Methods
In this examination, we analyzed 992 patients’ data, out 
of which 608 had been treated at the Cardiovascular De-
partment of the Semmelweis University from November 
2003 until June of 2005. All these patients underwent 
vascular surgical reconstruction because of their athero-
sclerotic disease – this was the only inclusion criteria of 
the examination. They had carotid-, thoracic-, abdomi-
nal-, or lower limb-revascularization or aneurysm repair. 
The common cause was atherosclerosis. We compared 
the data of 348 atherosclerotic non-diabetic patients and 
260 diabetic patients with the 384 healthy control sam-
ples. We analyzed the frequency of myocardial infarc-
tion and stroke in the case of different polymorphisms. 
All the 608 patients were divided into four groups: (1) 
atherosclerotic diabetic patients with myocardial infarc-
tion (n=101), (2) atherosclerotic diabetic patients with 
stroke (n=108), (3) atherosclerotic non-diabetic patients 
with myocardial infarction (n=118) and (4) atheroscle-
rotic non-diabetic patients witch stroke (n=106). The 
occurrence of all the hetero- and homozygote variants 
of the analyzed genes were tested in every group and the 
results were compared to the healthy control samples.
Isolation of DNA samples
DNA was extracted from the buffy coat fraction of cen-
trifuged blood using the QIAmp Blood Kit (Qiagen).
SNP analysis of eNOS G298T and MTHFR C677T
The following primers and probes were designed by 
LightCycler probe design software 2.0:
eNOS: sense primer: 5´-CAGCTCTGCATTCAG-
CAC-3 ;´ antisense primer: 5´-CATCCCAC-CCAGT-
CAATC-3´ sensor: 5´-LCRed640-GTTCTGGGGGCT-
CATCTGGG-PH-3´ (designed for the wild type allele); 
anchor: 5´-CAGCTCGGGGGGCAGAAGGAA-FL-
3 ;´MTHFR: sense primer: 5´-AGGCCAGCCTCTCCT-
GACTG-3 ;´ antisense primer: 5´-AGGACGGT-
GCGGTGAGAGTG- 3 ;´ sensor: 5´-CGGGAGCC-
GATTTCATCA-FL-3 ;´ anchor: 5´-LCRed640-CG-
CAGCTTTTCTTTGAGGCTGACA-PH.
Amplification of 50-ng DNA template with primers 
(0.5 μM each) and fluorescent probes (0.2 μM each) was 
performed in LightCycler instrument (Roche Diagnos-
tics GmbH) using LightCycler FastStart DNA Master 
HybProbe mix (Roche Diagnostics GmbH). The Mg-
Cl2 concentration was 2 mM. The cycling conditions 
of eNOS fragment were 95 °C and 10 min followed by 
Fig. 1.  eNOS G298T DNA melting curve analysis, eNOS G298T polymorphism determination
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45 cycles of 95 °C, 10 s; 65 °C; 5 s; and 72 °C, 5 s. The 
thermal profile of the MTHFR PCR was 95 °C and 10 
s followed by 45 cycles of 95 °C, 3 s; 52 °C, 5 s; and 
72 °C, 13 s. For the analysis of the melting curves at 
the end of the PCR,temperature was raised to 95 °C, 
lowered to 45 °C and then slowly raised to 85 °C whilst 
monitoring the fluorescence intensity. The negative first 
derivative of the melting curves created by the software 
(LC vs.3.5) made possible the distinction of the geno-
types (Figs 1 and 2).
Sequencing
Sequencing analyses were performed with the PCR 
products using the primers described in the SNP analy-
sis. The sequencing reactions were carried out by Big-
Dye terminator cycle sequencing kit v.3.1. (Applied 
Biosystems, Foster City, CA, USA) and the reaction 
products run in ABI-PRISM 3130 Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA).
TNF-a genotype analysis/SNP analysis
For TNF-α 308GA polymorphisms analysis, the next PCR 
primer was used: 5´-AGGCAATAGGTTGAGGGC-
CAT-3´ and 5´-TCCTCCCTGCTCCGATTCCG-3 .´
The 308 GA polymorphism analysis was performed 
by Fernandez-Real et al. [32]. We analysed the data sta-
tistically; we used two sides Student t-probe, odds’ ra-
tio, chi-square probe, average and scattering (SD) and 
graphical presentation. Those differences were signifi-
cant, where the statistical deviance was p<0.05.
The author of this article has certified that he com-
plies with the principles of ethical publishing [33].
Results
There was no significant difference: between the age 
of the patients in the compared groups. The mean age 
was 70 years in the diabetic group and 68 years in the 
atherosclerotic group. The youngest patient was 40 and 
the oldest patient was 93 years old. Half of the diabetic 
patients were treated by oral antidiabetics,while third of 
them were on insulin and 20% was only kept on diet. 
All patients had significantly higher cholesterol (5.2–
5.5 mmol/L), LDL (3.6–3.6) and triglicerid (2.2–1.9 
mmol/L) levels, in comparison with the the control 
group (3, 2.5 and 1 mmol/L). There was no differ-
ence in the occurrence of prior myocardial infarction 
between the diabetic and atherosclerotic non-diabetic 
groups (39.0% vs. 38.9%), but the stroke prevalence was 
significantly higher among the diabetic patients (20.0% 
vs. 38.0%, p < 0.05).
eNOS analysis
We specified the eNOS polymorphisms by DNA melting 
curve analysis at 384 healthy controls, 348 atheroscle-
rotic non-diabetic and 260 diabetic patients. A repre-
sentative DNA melting curve is shown in Fig. 1, where 
the different genotypes can be identified. The wild Glu/ 
Glu is GG genotype and the mutant Asp/Asp is TT gen-
otype amino acid sequence.
We examined the occurrence of the wild (GG), the 
mutant (TT) and the heterozygote (GT) allele in dif-
ferent illness-combinations. We verified that in the Asp 
298 allele homozygote TT variants, NO production is 
decreased and endothelial dysfunction can occur more 
often, resulting in higher risk for atherosclerosis. We 
have confirmed that in the case of eNOS 298 mutant 
Fig. 2.  MTHFR C677T polymorphism melting curve analysis
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TT variants, the prevalence of the myocardial infarction 
(MI) is significantly higher compared to the patients 
carrying the homozygote GG normal or heterozygote 
GT variants. Our tests show that the frequency of the 
eNOS 298 TT mutation in the control group is 5.7%. 
Among the diabetic patients with prior MI the fre-
quency is 14.8% (p < 0.05); while in the diabetic stroke 
patients it is 12.9% (p < 0.05). In the atherosclerotic 
non-diabetic MI patients, the allele occurrence is 16.9% 
(p < 0.05); while in the non-diabetic stroke group, we 
found it in 15.09%-of the patient (p < 0.05), we have 
also compared the homozygote TT to the homozygote 
GG frequency (Fig. 3). The case–control analysis (odds 
ratio) showed increased relative risk. The homozygote 
TT mutant allele carrying patients in the diabetic group 
have the risk of 3.34 (1.61–6.92) for MI and a risk of 
2.72 (1.31–5.66) for stroke. In the atherosclerotic non-
diabetic group, the MI risk is higher, 4.56 (2.29–9.08), 
but the stroke-risks are elevated, as well OR 3.74 (1.82–
7.71). Thus, high risk patients, who were Asp 298 ho-
mozygotes (TT), showed four times higher risk for MI 
than patients with normal GG allele. One of the impor-
tant results of our study is that we proved a close con-
nection between Glu298Asp polymorphisms, MI and 
stroke risk. We could verify a new gene polymorphism 
on the NOS3 gene and the Glu298Asp mutation proved 
to be a major risk factor for MI. This finding seems to be 
important but further confirmation is necessary in other 
patient groups [34].
MTHFR analysis
The MTHFR gene polymorphism were analyzed in 
384 controls, 260 diabetic and 348 atherosclerotic non-
diabetic patients was analyzed by melting curve analy-
sis with DNA LightCycler. We concluded that in the 
case of mutant MTHFR C677T variants the priorMI 
occured significantly more often. In our samples, the 
MTHFR 677 CT mutations occurred in 32% in the 
control group; while among the diabetic patients with 
prior MI the frequency was 53.5% (p<0.05); and in the 
diabetic stroke group it was 51.8% (p<0.05). Among 
the nondiabetic atherosclerotic patients with prior MI, 
the CT occurence was 55.1% (p<0.05) while among the 
stroke patients 53.7% carried the mutation, which is a 
significant difference (p<0.05) compared to our con-
trols.
The homozygote TT variant is less frequent in the the 
diabetic group but the difference is still significant, the 
frequency was 16.8% in the prior MI group (p<0.05) 
and 14.8% (p<0.05) in the prior stroke group. At the 
atherosclerotic non-diabetic patients group, the occur-
rence is highly significant again, in the prior MI group 
it is 21.2% (p<0.05) and in the stroke patients,19.8% 
(p<0.05) (Fig. 4).
When we examine all the mutant alleles (TT+CT) in 
every four patients’ groups in the relation to the normal 
CC variant, at every count, we found significant differ-
ence (p<0.05). In our study, we have established that 
the MTHFR C677T allele is a risk factor of stroke. Also, 
a relevant difference could be proved for the risk of MI. 
The sample number of this study was not enough to ver-
ify the hypothesis that MTHFR genotypes influence the 
development of the coronary sclerosis; more and larger 
studies are necessary to examine the connection be-
tween the the genetic and environmental factors. In this 
study, we can only establish that the MTHFR C677T 
polymorphism is associated with a significantly higher 
prevalence of MI and stroke. The case–control analysis 
of the diabetic, homozygote TT mutant allele carrying 
patients showed that the risk of MI was 2.95 (1.51–5.79) 
and the risk of stroke was 2.31 (1.18–4.52). In the ath-
erosclerotic nondiabetic group, the MI risk was higher, 
4.65 (2.48–8.72) and the stroke-risk was also elevated 
OR 3.91 (2.04–7.49) compared to the healthy controls.
Fig. 4.  MTHFR polymorphisms in the five groups. In the ath-
erosclerotic non-diabetic patient group, the rate of the 
mutant 677TT homozygote genotype and 677 CT het-
erozygote genotype is significantly higher to the wild type 
(Abbreviations: DM=diabetes, MI=myocardial infarc-
tion, ASO=atherosclerosis)
Fig. 3.  eNOS polymorphisms in the five groups. In the athero-
sclerotic non-diabetic patient group, the rate of the mu-
tant TT homozygote genotype is significantly higher 
to the control group (Abbreviations: DM=diabetes, 
MI=myocardial infarction, ASO=atherosclerosis)
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TNF-α analysis
In our study, we have established that the mutant TNF-α 
AA allele carrying patients have a significant higher risk 
for cardiovascular events than the control group. We 
could verify that in the healthy control samples the wild 
TNF-α 308 GG genotype occurrence was 76.7%, the 
heterozygote (308 GA) was 21.7%, while the mutant 
homozygote (308 AA) genotype accounted for only in 
1.6%. Our data show that in diabetic patients MI group 
(examined group 2) the mutant 308 AA frequency was 
elevated to 9.2% (p<0.05). In the examined group 3, 
the TNF-α genotype distribution was the following: 
the AA homozygote high-risk mutant in 7.7% (p<0.05), 
while the GA homozygote in 30.7%, against in the con-
trol groups, 61.6%. In all patients, carrying the A al-
lele, the TNF-α level can be higher, causing an elevated 
risk for cardiovascular events. In the examined groups 4 
and 5 there were atherosclerotic non-diabetic patients, 
MI and stroke patients. We could establish that the AA 
genotype occurrence in this group was higher (10.7%) 
(p<0.05) than in the control groups (1.6%) (Fig. 5).
The heterozygote GA allele occurrence was elevated 
at atherosclerotic patients (28%, 28.9%), in contrast to 
the 21.7% in the control group, At the odds ratio ex-
amination, we found an extreme high risk for MI and 
stroke in TT mutation carrying patients. Among the 
atherosclerotic non-diabetic patients, the MI risk was 
OR 6.714 (1.725–25.553) and the OR of stroke was 
6.714 (1.725–25.553). Among the atherosclerotic pa-
tients, the MI risk was high, OR 8.173 (2.242–29.559), 
while the stroke prevalence was the highest, OR 8.703 
(2.152–34.988) [35].
Discussion
The study resulted in the following new assumptions:
1. In patients carrying the eNOS Glu298Asp mutant 
homozygote TT variant, the MI occurrence was signifi-
cantly higherthan in the heterozygote GT and normal 
GG variant (TT allele: control group 5.7%, MI group 
16.9%, p < 0.05, OR: 4.56).
2. In the case of MTHFR 677 CT heterozygote vari-
ant, the MI prevalence was much higher (CT genotype: 
control group, 32%; MI group, 55.1%; p<0.05; OR: 
4.13), while in case of homozygote TT genotype the 
difference was still significant (TT allele: control group, 
10.9%; MI group, 21.2%; p<0.05; OR: 4.65).
3. Among the TNF-α AA allele carrying patients, 
the risk for cardiovascular events was significantly ele-
vated (AA allele: control group, 1.6%; MI group, 10.7%; 
p<0.05, OR: 8.17).
Screening the endangered or genetically high risk 
groups should be considered on the long run – an early 
detection of a susceptibility of the disease gives better 
chances for prevention and treatment. Understanding 
the inflammatory mechanisms of the atherosclerosis may 
give new therapeutic targets to pharmacologists. Thera-
peutic possibility of the statins today is available; they 
have anti-inflammatory, antithrombotic and plack-sta-
bilisatory effects. The anti-thrombotic medications like 
acetylsalicylic acid and clopidogrel are part of the anti-in-
flammatory treatment as well. In certain cases, the high 
level of plasma homocystein can be reduced with giving 
acidum folicum. Further clinical and pharmacological 
investigations are needed to identify the key-molecules 
in different pathomechanisms (tumor, inflammation) in 
order to find validated therapeutic targets.
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